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Ovarian clear cell carcinoma (OCCC) is a morphologically and biologically distinct subtype of ovarian carcinomas that
often arises in ovarian endometriosis. We previously reported that a unique carcinogenic environment, especially iron-
induced oxidative stress in endometriotic cysts may promote development of OCCC. We also identified a gene expression
profile characteristic of OCCC (the “OCCC signature”). This 320-geneOCCC signature is enriched in genes associatedwith
stress response and sugar metabolism. However, the biological implication of this profile is unclear. In this study, we have
focused on the biological role of the HNF-1b gene within the OCCC signature, which was previously shown to be
overexpressed in OCCC. Suppression of HNF-1b in the HNF-1b-overexpressing human ovarian cancer cell line RMG2 using
short hairpin RNA resulted in a significant increase in proliferation. It also facilitated glucose uptake, glycolytic activity, and
lactate secretion along with increased expression of the glucose transporter-1 (GLUT-1) gene and several key enzymes in
the glycolytic process. Conversely, forced expression of HNF-1b in the serous ovarian cancer cell line, Hey, resulted in
slowed cellular growth and repressed glycolytic activity. These data suggest that HNF-1b represses cell growth, and at the
same time, it promotes aerobic glycolysis which is known as the “Warburg effect.” As the Warburg effect is regarded as a
characteristic metabolic process in cancer which may contribute to cell survival under hypoxic conditions or in a stressful
environment, overexpression of HNF-1b may play an inevitable role in the occurrence of OCCC in stressful environment.
© 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Ovarian cancer is the leading cause of death among
gynecologicalmalignancies. Epithelial ovarian cancer
consists of four histologically distinct subtypes,
namely, serous, mucinous, endometrioid, and clear
cell carcinoma. Ovarian clear cell carcinoma (OCCC)
has distinct clinical features as compared to other
subtypes: it is generally chemo-resistant, is often
accompanied by a thromboembolic complications,
and shows slow growth but with unfavorable out-
comes. The most notable feature of OCCC is its
relationship with ovarian endometriosis. According
to epidemiological surveys, approximately 1% of
ovarian endometriosis eventually transforms into
carcinoma, primarily of the clear cell and endome-
trioid subtypes. This strongly suggests that there is a
specific carcinogenic trajectory that directs the
malignant transformation of endometriosis [1–6].
We previously reported that the unique composi-
tion of endometriotic cyst fluid, especially the high
free iron concentration, promotes carcinogenesis
through persistent oxidative stress [7]. We also
identified a microarray-based gene signature that is
specific to OCCC, which we designated as the “OCCC
signature.” Analyses of the OCCC signature revealed
that OCCC-specific gene expression is characterized
by the involvement of many stress-related genes,
which further supports the association between
OCCC and stress. Pathway analysis of the OCCC
signature demonstrated that an intracellular signal-
ing pathway consisting of a large number of genes,
especially stress-related genes, is activated inOCCC. A
second prominent gene category overrepresented in
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the OCCC signature is metabolism-related, in partic-
ular glycogen-related genes, suggesting that OCCC
has a distinct metabolic character among the ovarian
carcinomas [8]. In this context, our next goal was to
characterize the genes responsible for this unique
expression profile and define the function of these
genes, which may then provide the basis for develop-
ment of targetedmolecular therapy that is specific for
OCCC. In this study, we have chosen to focus on a
specific OCCC signature gene, hepatic nuclear factor-
1b gene (HNF-1b).
HNF-1b is a homeodomain-containing transcrip-
tion factor that shares >80% amino acid sequence of
homeodomain [9] homology with HNF-1a. These
proteins dimerize andbind to the sameDNA sequence
as homodimers or heterodimers, and are known to
regulate the expression of multiple genes through
direct or indirect mechanisms [9]. Clinically, HNF-1
mutations are responsible for “maturity-onset diabe-
tes of the young (MODY),” a specific type of diabetes
characterized by pancreatic hypoplasia. Diabetes has
been reported in 58% of HNF-1b mutation carriers
[10]. HNF-1b has been implicated in the development
of the pancreas and is thought to be an essential
regulator of the transcriptional network that controls
pancreatic morphogenesis and the differentiation of
pancreatic endocrine cells [11].
Tsuchiya et al. recently reported that HNF-1b is
overexpressed in OCCC. Although they identified an
anti-apoptotic effect of this gene, the precise mecha-
nism and biological significance of HNF-1b in OCCC
are not yet clear [12]. We have shown that HNF-1b is
not only a component of the OCCC signature [8], but
also included in the intracellular signaling network
demonstrated by pathway analysis, suggesting that
this gene plays an important role in the biology of
OCCC [13]. Therefore, using HNF-1b knockdown in
OCCC cells and HNF-1b overexpression in non-
OCCC cells, we report herein elucidation of how
HNF-1b functionally plays a role in the unique
biology of OCCC from multiple point of view
including cell proliferation, glucose metabolism and
gene expressions.
MATERIALS AND METHODS
Cell Lines and Cell Culture
The OCCC cell lines, RMG1 and RMG2, and the
serous carcinoma cell line, Hey, were cultured in
RPMI1640 (Nikken, Kyoto, Japan) supplementedwith
10% FBS in a humidified atmosphere containing 5%
CO2 at 378C, as previously described [8].
Stable Knockdown and Overexpression of the HNF-1b
Gene
Two HNF-1b-targeting short hairpin RNAs (shRNA;
clone IDs: V2LHS_204881 and V2LHS_196459) and
a non-silencing control (clone ID: RHS4348)
were purchased from the GIPZ lentiviral shRNAmir
library (Thermo Fisher Scientific, Huntsville, AL).
RMG2 cells were infected with lentiviruses using a
standard protocol using puromycin as the selective
marker. RMG2 cells stably transfected with clones
V2LHS_204881 or V2LHS_196459 were designated
as RMG2-HNFb-sh1 and RMG2-HNF1b-sh2, respec-
tively, while RMG2 cells transfected with the non-
silencing control were designated as RMG2-control.
HNF-1b-suppressed stable cells in RMG1 cell line were
established using samemethod above and designated
as RMG1-HNF1b-sh1 while non-silencing control
cells were designed as RMG1-control. For HNF-1b-
overexpressing cell line, an HNF-1b-expressing lenti-
virus was constructed using an entry vector,
pENTR221, containing the HNF-1b cDNA (Cat. No.
OHS4559-99857765a; Thermo Fisher Scientific), and
a destination vector, pLenti6/V5-DEST, in a Gateway
system (Invitrogen Japan, Tokyo, Japan). Hey cells
were infected with the HNF-1b-expressing lentivirus
and were selected with blasticidin (Hey-HNF1b). The
Hey cells transfected with an empty lentiviral vector
were used as a control (Hey-control).
RNA Extraction and Quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR)
Total RNA was isolated from cells at 80% conflu-
ency using the RNeasy Mini Kit (Qiagen, Tokyo,
Japan). Quantitative RT-PCR (qRT-PCR) was per-
formed with primers and probe specific for HNF-1b
(Assay ID: Hs00172123_ml) and SOD1 (Assay ID:
Hs00533490_m1; Taqman Gene Expression Assays;
Applied Biosystems, Foster City, CA). All other assays
were designed using Roche Probefinder software
at the Universal Probe Library Assay Design Center
(https://www.roche-applied-science.com/sis/rtpcr/
upl/index.jsp?id¼UP030000). Primer and probe se-
quences are provided in Supplementary Table 1. The
samples were analyzed using a LightCycler 480 Real-
Time PCR system (Roche Diagnostics, Tokyo, Japan).
Protein Extraction and Western Blot Analysis
Protein extraction and Western blotting were
performed as reported previously [13] using the
following primary antibodies: anti-HNF-1b (1:200;
Santa Cruz, CA), anti-CDKN1B (1:1000, BD Biosci-
ence, Franklin Lakes, NJ), anti-CDKN1A (1:200; Santa
Cruz, CA), anti-GLUT1 (1:2500, Abcam Plc, Cam-
bridge, UK), and anti-b-Actin (1:5000, Abcam Plc).
Horseradish peroxidase-linked secondary antibodies
were as follows: anti-goat Ig for HNF-1b (1:10 000,
DAKO,Glostrup, Denmark) andCDKN1A (1:3000, GE
Healthcare, Buckinghamshire, UK), anti-mouse Ig for
CDKN1B (1:1000, GE Healthcare) and GAPDH
(1:1000, Santa Cruz, CA), anti-rabbit Ig for GLUT1
and b-actin (1:2500 and 1:10000, respectively,
GE Healthcare). Images were obtained using a
ChemiDoc XRS Plus system (Bio-Rad Laboratories,
Tokyo, Japan).
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Proliferation Assays
Cells were seeded into 96-well (2.5103 cells/well)
tissue culture plates and incubated for 3 d. Cell
numbers were counted at three consecutive time
points using a WST-8 (Water Soluble Tetrazolium
salts) assay kit, which is a modified MTT (3-(4,5-
di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay (Nakalai tesque, Kyoto, Japan). WST-8
assay values were normalized using the WST-8 value
at the initial time point (Day 0), and compared
between the groups. Population doubling times (PDT)
were calculated based on the slope angle of the linear
regression model for the three time points. In
addition to WST-8 assays, cell numbers were directly
counted in sextuplicate using the Countess Automat-
ed cell counter (Invitrogen) after the cells were seeded
into 6-well tissue culture plates (3.0105 cells/well)
and incubated for 2, 5, and 11 d. The values were
normalized at the initial time point (Day 0) same as
above.
The Cell Cycle Analysis
The cell cycle analysis was performed as described
previously [14]. The cells (1106/well) were seeded in
10 cm2 tissue culture dishes and cultured. The next
day, cells were treated by nocodazole (Sigma–Aldrich,
St. Louis, MO) at a final concentration of 0.5mg/mL.
After incubation for 0, 12, 24h, cells were fixed with
70% ethanol, stained with 25mg/mL propidium
iodide (Sigma–Aldrich) and analyzed by FACS-Calibur
flow cytometry with Cell Quest software (Becton
Dickson, Franklin Lakes, NJ). For analysis of S-phase
cell, cells were pulse-labeled with 10mM BrdU for 1h,
fixed with 70% ethanol, denatured, and stained with
APC conjugated Anti-BrdU Antibody (Becton Dick-
son), according to manufacturer’s instructions.
Glucose Uptake Assay and Measurement of Lactate
Production
Glucose uptake assays were performed as reported
previously [15]. In brief, cells were incubated with
glucose-free medium with 1mCi 2-deoxy-[3H]-D-glu-
cose for 60min. The cells were then washed three
times with ice-cold PBS, collected, and quantified
using a liquid scintillation counter. Lactate produc-
tionwas evaluated bymeasuring the concentration in
the medium after 24h of incubation. The assay was
performed in triplicate, repeated three times and
all the values were normalized by total protein
concentration.
Glycolytic Flux Measurement
Measurement of glycolytic flux was performed as
reported previously [16]. In brief, 0.7–3.0106 cells
were plated in a 10 cm2 dish. The medium was
changed the following day to a low-glucose
(4.25mmol/L) medium, and 12h later, D-[3-3H]
glucose (3.6mCi) was added. Every 2h, 400mL of
the medium was taken for perchloric acid precipita-
tion. The supernatant was applied to DOWEX
18 200–400 MESH Cl resin (Sigma–Aldrich Japan)
after dilution in sodium tetraborate. The assay
was performed in triplicate, repeated three times
and the values were normalized by total protein
concentration.
Glucose Uptake After Knockdown of GLUT1 in RMG2
Cells
GLUT1-specific siRNAs (Gene Solution siRNA, Cat.
No. SI03089401 and No. SI00089264; Qiagen, Valen-
cia, CA) and a negative-control siRNA (AllStars
Negative Control siRNA; Qiagen) were transfected
into RMG2 cells usingHiPerFect Transfection Reagent
(Qiagen). After 48h incubation for with the siRNAs,
glucose uptake assays were performed as described
above. To confirm downregulation of GLUT1 expres-
sion, qRT-PCR and Western blotting were performed
as described above.
Microarray Analysis
RNA preparation and microarray analysis were
performed as described [8,13]. Genome set Human
U133 Plus 2.0 chips (Affymetrix, Santa Clara, CA)
were used and expression of HNF-1b-knockdown and
non-silencing control cells were compared using
replicate cell preparations (five replicates each for
RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2, ten repli-
cates for the RMG2-control). The enrichment of the
OCCC signature in control (non-silencing) cells
versus HNF-1b-knockdown cells was evaluated using
Gene Set Enrichment Analysis (http://www.broad-
institute.org/gsea/index.jsp; GSEA). GSEA is a tool to
determine if a particular set of pre-defined genes is
over- or under-represented in a given sample. Here,
probe sets that were previously shown [8] to be
upregulated (n¼393) and downregulated (n¼44)
were analyzed in RMG2 cells following knockdown of
HNF-1b using two independent shRNAs. Interpreta-
tion of output figures is described in detail in theGSEA
website (http://www.broadinstitute.org/gsea/index.
jsp). Bayesian binary regression 2.0 (http://data.
genome.duke.edu/oncogene.php) was used to calcu-
late the HNF-1b signature probability scores of cells,
indicating transcriptional pathway activity ofHNF-1b
downstream genes. Published microarray dataset
GSE6008 (consisting of data from 8 OCCC and 91
non-OCCC specimens) was obtained from the Gene
Expression Omnibus (GEO) website (http://www.
ncbi.nlm.nih.gov/geo/). The GSE2109 dataset was
also obtained from the GEO website, and 16 OCCC
and 184 non-OCCC (excluding borderline tumors)
were used for this analysis. Cell lines used in the
present study are listed in Supplementary Table 2.
Statistical Analysis
Differences between groups were assessed using
two-tailed unpaired t-tests. Data are represented
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as mean standard deviation (SD). Statistical analy-
sis was performed using GraphPad Prism 4 software
(GraphPad Software, Inc., La Jolla, CA), and pro-
bability values below 0.05 were considered as
significant.
RESULTS
Effect of HNF-1b Knockdown on In Vitro Cell Proliferation
Expression of HNF-1b mRNA in shRNA-transfected
cells was evaluated using qRT-PCR. HNF-1b expres-
sion was significantly suppressed (% suppression is
87.3% in RMG2-HNF1b-sh1 (P¼0.009) and 71.6%
in RMG2-HNF1b-sh2 (P¼0.013) compared with
the RMG2-control cells (Figure 1A). Suppression of
HNF-1b protein was also confirmed by Western blot
(Figure 1A).
Silencing ofHNF-1bwas associatedwith an increase
in cell proliferation in RMG2 cells as detected using
WST-8 assays (P<0.01; Figure 1B) and based on cell
counts (P<0.0001; Figure 1B). PDT of RMG2-HNF1b-
sh1, RMG2-HNF1b-sh2, and RMG2-control cells
were 27.2, 21.5, and 34.5h, respectively, as assessed
by WST-8 assays, and were 1.94, 1.43, and 2.37 d,
respectively, based on direct cell counts.
The suppression of HNF-1b in another OCCC cells,
RMG1 (% suppression was 72.8% in RMG1-HNF1b-
sh1 (P¼0.041; Figure 2A)) also caused accelerated cell
proliferation as compared to control cells (P<0.0001;
Figure 2B). PDT of RMG1-HNF1b-sh1 and RMG1-
control cells by WST-8 assays were 41.9 and 65.2h,
respectively.
Effect of HNF-1b Knockdown on Cell Cycle Progression
and the Expression of CDKN1A and CDKN1B
We evaluated cell cycle progression by using
Nocodazole, which arrests cell cycle at G2/M phase.
Non-silencing RMG2 cells were significantly retarded
in the transition G1/S to G2/M phase after 12, 24h
incubation with Nocodazole, compared to HNF-1b-
knockdown RMG2 cells (Figure 1C). In addition, the
detection of BrdU incorporation revealed that the
percentage of S-phase cell was significantly reduced in
19.9% in RMG2-control cells, compared with 29.1%
in RMG2-HNF1b-sh1 and 28.9% in RMG2-HNF1b-
sh2 (Figure 1D).
Since HNF-1b knockdown resulted in an increase in
cell proliferation in RMG2 cells, we evaluated
CDKN1A and CDKN1B expression in HNF-1b-knock-
down and non-silencing RMG2 cells byWestern blot.
CDKN1B protein levels in both RMG2-HNF1b-sh1
and RMG2-HNF1b-sh2 were significantly repressed as
compared with the RMG2-control cells (% suppres-
sions were 61.9% and 81.8%, respectively; Figure 1E).
CDKN1A protein levels were also suppressed in
RMG2-HNF1b-knockdown cells compared with
RMG2-control cells (% suppressions were 81.9% and
83.1%, respectively; Figure 1F).
Effect of HNF-1b Knockdown on Glucose Uptake,
Glycolytic Flux, and Lactate Secretion
The rate of glucose uptake was measured using
a scintillation counter and normalized to that of
non-silencing control cells. Uptake of extracellular
glucose was significantly decreased in HNF-1b-knock-
down cells as compared to control cells (RMG2-
HNF1b-sh1, 42.66.56%, P¼0.0019; RMG2-HNF1b-
sh2, 40.25.29% P¼0.0014; Figure 3A).
To verify that HNF-1b promotes glycolytic activity,
we further examined glycolytic flux, which was
determined by measuring the rate per hour of
conversion of 3H-labeled glucose to H2O through
the glycolytic pathway (Figure 3B). Glycolytic flux
was significantly decreased in HNF-1b-knockdown
cells as compared to control cells (RMG2-HNF1b-sh1,
56.08.78%, P¼0.0012; RMG2-HNF1b-sh2, 49.8
2.56%, P<0.0001; Figure 3B).
Lactate secretion into the culture media was also
measured and was significantly suppressed in HNF-
1b-knockdown cells (RMG2-HNF1b-sh1, 70.0
6.46%, P¼0.030 and RMG2-HNF1b-sh2, 45.2
8.53%, P¼0.0047) relative to the control cells
(Figure 3C).
We also analyzed the effect of HNF-1b on glucose
metabolism using another OCCC cell line, RMG1.
Glucose uptake (69.01.60%, P¼0.0008; Figure 3D),
glycolytic flux (71.51.35%, P¼0.0003; Figure 3E)
and lactic acid production (60.00.98%, P<0.0001;
Figure 3F) in RMG1-HNF1b-sh1 cells were also
significantly suppressed compared to control cells.
Effect of HNF-1b Overexpression on Cell Proliferation,
Glucose Uptake, Glycolytic Flux, and Lactate Secretion
Expression of HNF-1b was determined by qRT-PCR
and Western blot following transfection of the HNF-
1b gene construct into Hey ovarian cancer cells. Both
themRNA andprotein levels weremarkedly increased
in Hey-HNF1b compared with the Hey-control cells
(Figure 2A). Forced expression of HNF-1b in Hey cells
led to a decrease in cell proliferation, as measured
using the WST-8 assay (P¼0.0003; Figure 2B). The
PDT of Hey-control and Hey-HNF1b was 11.9 and
14.9h, respectively.
Glucose uptake was significantly increased in
Hey-HNF1b cells when compared with Hey-control
cells (23165.2% vs. 10028.8%, P¼0.0334;
Figure 3G). Hey-HNF1b cells also exhibited en-
hanced glycolytic flux relative to the Hey-control
cells (1207.26% vs. 1002.84%, P¼0.0099;
Figure 3H).
Lactate production over the course of 24h was also
elevated in Hey-HNF1b cells compared with that in
Hey-control cells (1187.74% vs. 1008.37%,
P¼0.0028; Figure 3I).
Moreover, forced expression of HNF-1b in the
immortalized human ovarian surface cell line
(HOSE/E7/hTERT) showed a similar result as Hey
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Figure 1. Short hairpin RNA mediated knockdown of HNF-1b expression enhanced cell proliferation rates with
suppression of CDKN1A andCDKN1B protein expression and progressed cell cycle theG1/S toG2/Mphase. (A)HNF-
1bmRNA expression detected by quantitative RT-PCR (left panel). HNF-1b protein expression detected by Western
blot analysis (right panel). (B) Cell proliferation curve produced from results of the WST-8 assay (left panel). Cell
proliferation curve produced by direct cell counts (right panel). x-axis, incubation time; y-axis, relative number cells in
log2 scale. In detail, relative number cells are determined asWST-8 value (number of cells) divided byWST-8 (number
of cells) value at 0 h (0 d). (C) Cell cycle analysis using PI after 12, 24 h nocodazole treatment. (D) The cell cycle analysis
using BrdU incorporation. (E) CDKN1B protein expression by Western blot analysis. (F) CDKN1A protein expression
by Western blot analysis. The right panels of (E) and (F) showed the quantified protein expressions which were
normalized with the expression in control cells. RMG2-sh1, RMG2-HNF1b-sh1; RMG2-sh2, RMG2-HNF1b-sh2; G1,
G1 phase; G3, G3 phase; P< 0.01.
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cell in glucose uptake, glycolytic flux and lactate
production (Supplementary Figure 2).
Effect of HNF-1b Knockdown and Overexpression on
GLUT1 Expression
GLUT1 mRNA expression in HNF-1b-knockdown
RMG2 cells was evaluated by qRT-PCR and found to
be repressed as compared to the control cells (RMG2-
HNF1b-sh1, 36.30.19%, P¼0.0001 and RMG2-
HNF1b-sh2, 40.50.20%, P¼0.0001; Figure 4A).
Likewise, the expression of GLUT1 protein was also
lower in the HNF-1b-knockdown cells than that
observed in the non-silencing control cells (Figure
4B). In addition, the mRNA expression of GLUT1 in
RMG1-HNF1b-sh1 was also decreased as compared to
control cells (84.94%1.25%, P¼0.035; Figure 4C).
GLUT1 protein expression was also suppressed in
RMG1-HNF1b-sh1 (Figure 4D).
Inversely, the expression of GLUT1 mRNA in Hey-
HNF1b cells was more than 2-fold higher than that in
Hey-control cells (22811.2% vs. 1000.98%,
P¼0.0073; Figure 4E). GLUT1 protein expression
was also elevated in the HNF-1b-overexpressing cells
(Figure 4F).
Effect of HNF-1b Suppression on Glycolytic Enzymes and
HIF-1a Expression
Messenger RNA expression levels of most of the
glycolytic enzymes (Hexokinase1 (HK1), Hexokinase2
(HK2), Glucose-6-phosphate isomerase (GPI), Phos-
phofructokinase liver type (PFK-L), Phosphofructoki-
nase platelet type (PFK-P), Aldolase A (ALDOA),
Aldolase B (ALDOB), Aldolase C (ALDOC), Triose-
phosphate isomerase (TPI), Phosphoglycerate kinase
1 (PGK1), Phosphoglycerate kinase 2 (PGK2), Phos-
phoglycerate mutase 1 (PGAM1), Enolase 2 (ENO2),
Enolase 3 (ENO3), Lactose dehydrogenase A (LDHA),
Lactose dehydrogenase B (LDHB)) were significantly
decreased in RMG2-HNF1b-sh1 cells as compared
with the RMG2-control group (Figure 5).
Since HIF-1a is implicated in the stress-resistance in
several cell lines, we examined if HNF-1b affects HIF-
1a expression. Expression levels ofHIF-1amRNAwere
not significantly different between RMG2-HNF1b-
sh1, RMG2-HNF1b-sh2, and RMG2-control cells
(Supplementary Figure 3).
Effect of HNF-1b Suppression on OCCC Signature
OCCC signature upregulated genes (393 probe sets)
were significantly enriched in the non-silencing
control cell group as compared with the HNF-1b-
knockdown cells (RMG2-HNF1b-sh1, RMG2-HNF1b-
sh2; FDRq-value<0.0001 and <0.0001, respectively;
Figure 6A). OCCC signature downregulated genes (44
probe sets) were significantly enriched in the HNF-1b-
knockdown cells when compared with the non-
silencing control cells (FDRq-value¼0.0019 and
0.0051, respectively; Figure 6B). These data indicate
that by suppressing HNF-1b activity, the OCCC
signature profile is altered in a manner that more
closelymatches thenon-OCCCgene signature profile.
Creation of an HNF-1b Signature From
HNF-1b-knockdown Microarray Data
We analyzed the gene expression microarray data
derived from the HNF-1b-knockdown cells and the
Figure 1. (Continued)
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non-silencing control cells using Bayesian binary
regression 2.0, and derived an HNF-1b signature that
consists of 250 probe sets (Supplementary Table 3)
that are differentially expressed between these two
groups (Figure 6C and D). The HNF-1b signature was
able to distinguish OCCC from non-OCCC in the
clinical ovarian cancer dataset GSE6008 (HNF-1b
signature probability, 0.9340.0378 in OCCC vs.
0.4230.208 in non-OCCC, P<0.0001) and in
dataset GSE2109 (HNF-1b signature probability,
0.6320.297 in OCCC vs. 0.4780.224 in non-
OCCC, P¼0.0112), as well as in the ovarian cancer
cell line dataset KyotoOv [8] (HNF-1b signature
probability, 0.6100.196 in OCCC vs.0.4090.221
in non-OCCC, P¼0.012; Figure 6D).
Effect of GLUT1 Knockdown on Glucose Uptake of RMG2
Cells
KnockdownofGLUT1was performedusingGLUT1-
specific siRNAs (siRNA1, siRNA2). Over 41.8%
(siRNA1) and 49.6% (siRNA2) knockdown of GLUT1
expressionwas achieved asmeasured by qRT-PCR and
87.7% (siRNA1) and 61.7% (siRNA2) reduction in
GLUT1 protein levels measured by Western blot
(Supplementary Figure 1A and B). Glucose uptake
following GLUT1 suppression was decreased relative
to that observed in the cells receiving the negative-
control siRNA (siRNA1, 73.77.72%, P¼0.0074;
siRNA2, 70.86.28%, P¼0.0030; Supplementary
Figure 1C).
Effect of HNF-1b Suppression on the Expression of
Superoxide Dismutase 1 (SOD1)
In the microarray data derived from the HNF-1b-
knockdown cells and the non-silencing control cells,
the expression of SOD1, which is one of oxidative
stress genes, were significantly suppressed in RMG2-
HNF1b-sh1 cells (P<0.0001) and RMG2-HNF1b-sh2
cells (P¼0.0002) as comparedwith the RMG2-control
(Figure 6F).
Further, we validated the SOD1 mRNA expression
by using qRT-PCR. The expression was significantly
decreased in RMG2-HNF1b-sh1 cells (P¼0.0012) and
RMG2-HNF1b-sh2 cells (P¼0.0001) as compared
with the RMG2-control (Figure 6G). Using another
OCCC cell line, RMG1, HNF-1b suppression also
caused decrease in mRNA expression of SOD1 genes
(P¼0.029; Figure 6G).
The expression of Glutathione peroxidase (GPX),
which is also one of the oxidative stress genes, was
also decreased in HNF-1b-suppressed cells (Supple-
mentary Figure 4).
DISCUSSION
We previously identified an OCCC-specific gene
expression signature that contains multiple genes
with functional relevance to the biology of clear cell
carcinomas, including HIF-1a, IL-6, and HNF-1b. In
this study, we focused on the role of HNF-1b in OCCC
for several reasons. First, HNF-1b is overexpressed
Figure 2. Knockdown of HNF-1b in RMG1 cells and forced expression of HNF-1b in Hey cells also affected the cell
proliferation rate. (A) HNF-1b mRNA expression detected by quantitative RT-PCR (left and central panel). HNF-1b
protein expression by Western blot analysis (right panel). (B) Cell proliferation curve produced from results of the
WST-8 assay. RMG1-sh1, RMG1-HNF1b-sh1; P< 0.05. Experiments were done three times in triplicate.
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Figure 3. Knockdown of HNF-1b in RMG2 and RMG1 cells was associated with the decrease of glucose uptake,
glycolytic flux, and lactate secretion. Conversely, forced expression of HNF-1b in Hey cells was associated with the
increase of them. (A) Glucose uptake in RMG2 cells. (B) Glycolytic flux in RMG2 cells (left panel). Scheme of simplified
glycolytic pathway (right panel). (C) Lactate secretion in RMG2 cells. (D) Glucose uptake in RMG1 cells. (E) Glycolytic
flux in RMG1 cells. (F) Lactate secretion in RMG1 cells. (G) Glucose uptake in Hey cells. (H) Glycolytic flux in Hey cells.
(I) Lactate secretion in Hey cells. RMG2-sh1, RMG2-HNF1b-sh1; RMG2-sh2, RMG2-HNF1b-sh2; RMG1-sh1, RMG1-
HNF1b-sh1. P< 0.05.
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specifically in the clear cell histologic type of
epithelial ovarian cancer [12,17–19], which we also
confirmed by gene expressionmicroarray and RT-PCR
[8]. Second, we have shown that the expression of
HNF-1b is epigenetically regulated [8,20], which is an
important and pharmacologically reversible feature
of many cancer-associated genes. Third, activation of
the HNF-1b signaling network was strongly predicted
from the pathway analysis of the OCCC signature,
indicating that HNF-1b is a central mediator of the
OCCC-specific signaling network [8,13]. Finally,
transcription factor binding motif analysis showed
that HNF-1b bindingmotifs are significantly enriched
among genes that comprise the OCCC signature [13].
Taken together, these findings strongly suggested
that HNF-1b plays a central role in the manifestation
of the unique biological phenotype of OCCC, but
the mechanisms driving this have been thus far
unclear.
To begin a functional analysis of HNF-1b in OCCC,
we chose to use RMG2, a human OCCC cell line,
because it phenotypically resembles clinical OCCC
and is also thought to be best representative of OCCC
from the context of gene expression profiles as
measured by microarray analyses. Knockdown of
HNF-1b expression in RMG2 cells using lentiviral
transfer of gene-specific shRNAs resulted in a marked
shift in theOCCC signature toward a non-OCCCgene
expression profile, suggesting that, as predicted, HNF-
1b is a key molecule in maintaining an OCCC
biological phenotype (Figure 6A and B). To confirm
the significance of HNF-1b in OCCC, we also used
binary regression 2.0 to develop an HNF-1b gene
signature using gene expression microarray data
obtained from HNF-1b-knockdown and control cells.
The HNF-1b gene signature consists of the group of
genes that are differentially expressed between the
HNF-1b-knockdown and control RMG2 cells, and has
Figure 4. HNF-1b upregulated GLUT1 expression. Knockdown of HNF-1b expression in RMG2 suppressedGLUT1
mRNA (A) and protein (B). Knockdown of HNF-1b expression in RMG1 suppressed GLUT1 mRNA (C) and protein
expression (D). Forced expression of HNF-1b in Hey cells increased GLUT1 mRNA (E) and protein expression (F).
RMG2-sh1, RMG2-HNF1b-sh1; RMG2-sh2, RMG2-HNF1b-sh2; RMG1-sh1, RMG1-HNF1b-sh1. P< 0.05.
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Figure 5. Effect of HNF-1b suppression on glycolytic enzymesMessenger RNA expression ofHK1,HK2,GPI, PFK-L,
PFK-P,ALD-A,ALD-B,ALDOC, TPI, PGK1, PGK2, PGAM 1, ENO2, ENO3, LDHA, and LDHBwere decreased in RMG2-
HNF1b-sh1 (right bar) cells, relative to RMG2-control cells (left bar). HK, hexokinase; GPI, glucose-6-phosphate
isomerase; PFK-L, phosphofructokinase liver type; PFK-P, phosphofructokinase platelet type; ALD, aldolase; TPI,
triosephosphate isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate kinase;
PGAM, phosphoglycerate mutase; ENO, enolase; PKM, pyruvate kinase muscle type; LDH, lactate dehydrogenase.
P< 0.05. Experiments were done in duplicate.
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the ability to distinguish OCCC from non-OCCC in
both ovarian cancer cell line datasets and important-
ly, clinical ovarian cancer datasets (Figure 6C–E).
These results support that HNF-1b plays a pivotal role
in the biology of OCCC. In addition, a total of 23
genes including HNF-1b were overlapped between
OCCC- and HNF-1b signature. Among them, eight
genes (ELOVL6, FXYD2, IVNS1ABP, LIPC, MED28,
MITF, RELN, TNFAIP6) have HNF-1 binding element
(V$HNF1 01) by analyzing with GATHER software
(http://gather.genome.duke.edu/). We also analyzed
these 23 genes by DAVID software (http://david.abcc.
ncifcrf.gov/), and found that genes belonging to
GO slim terms related to cell proliferation and
Figure 6. Gene expressionmicroarray analysis showed that HNF-1b is a keymolecule determining theOCCCgene
expression profile. (A and B) Gene Set Enrichment Analysis. The x-axis represents rank of genes comprising of a
particular gene set (signature genes) among the whole genes in the genome. Each vertical black line represents on
signature genes, and the degree to which the black lines are deviated to the left or right indicates the statistical
significance regarding increased expression of the signature genes in a particular group of samples (designated as
enrichment). The y-axis represents Enrichment Score (ES) of the individual signature genes. Shift of the green line
curve to the upper left indicates enrichment in the left, and shift to the lower right indicates enrichment in the right.
(A) Left x-axis; Individual upregulated genes within the OCCC signature are shown as vertical black lines to see their
deviation compared to the whole genes in the genome between the left (control shRNA samples, n¼ 10) and the
right (HNF1b-sh1, n¼ 5). The genes comprising of this gene set were shifted to the left, which indicates enrichment
in the RMG2-control-sh samples as compared to RMG2-HNF1b-sh1 samples (FDRq-value< 0.0001). (A) Right;
Similarly, the upregulated genes within the OCCC signature were enriched in the RMG2-control-sh samples (n¼ 10)
as compared to the RMG2-HNF1b-sh2 samples (n¼ 5) (FDRq-value< 0.0001). (B) The downregulated genes within
the OCCC signature were significantly enriched in RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2 cells as comparedwith
RMG2-control cells (FDRq-value¼ 0.0019 and 0.0051, respectively). (C) Analysis using Bayesian binary regression.
The HNF-1b signature was generated from 250 probe sets shown in each row. Red to blue indicates high to low
expression. Each column represents an individual cell line. Ten columns on the left side represent shRNAs (both
RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2 cells) and the ten columns on the right side represent RMG2-control cells.
(D) Leave-one-out cross-validation of training sets (RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2 cells versus RMG2-
control) using the HNF-1b signature genes. Blue and red colors indicate RMG2-HNF1b-sh cells (n¼ 10) and RMG2-
control cells (n¼ 10), respectively. The probability estimates based on the HNF-1b signature genes is shown on the
vertical axis with 95% confidence intervals. (E) OCCC has a higher probability of having the HNF-1b signature profile
than non-OCCC. GSE6008 (0.93 0.038 vs. 0.42 0.21, P< 0.0001); GSE2109 (0.63 0.30 vs. 0.48 0.22,
P¼ 0.0112); KyotoOv (0.61 0.20 vs. 0.41 0.22, P¼ 0.012). (F) The expression of SOD1 gene (probe ID:
200642_at) is significantly decreased in RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2 cells as compared to control cells
(P< 0.0001 and P¼ 0.0002, respectively). (G) The validation of SOD1 gene expression by qRT-PCR. RMG2-HNF1b-
sh1 and RMG2-HNF1b-sh2 cells versus RMG2-control cells (P¼ 0.0012 and P¼ 0.0001, respectively). RMG1-
HNF1b-sh1 versus RMG1-control cells (P¼ 0.029). RMG2-sh1, RMG2-HNF1b-sh1; RMG2-sh2, RMG2-HNF1b-sh2;
RMG1-sh1, RMG1-HNF1b-sh1. P< 0.05.
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metabolism such as “negative regulation of cell
proliferation (P¼0.09),” “carbohydrate binding
(P¼0.062),” and “regulation of cellar response to
stress (P¼0.009)” were enriched in these 23 genes.
Then, we tested if HNF-1b suppression affects cell
proliferation andnotably found that this significantly
increases the growth rate of RMG2 cells. Moreover,
transfection of the HNF-1b gene into Hey, a serous
Figure 6. (Continued)
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ovarian cancer cell line with minimal HNF-1b
expression, caused cell growth to be significantly
decreased. These data suggest that HNF-1b functions
as a suppressive regulator of cell proliferation. We
then evaluated whether HNF-1b suppression causes
leads to altered expression of the cell cycle regulator,
CDKN1A and CDKN1B, and found that it causes
marked reduction of CDKN1A and CDKN1B levels,
suggesting that HNF-1b negatively controls cell
proliferation by inducing expression of a potent cell
cycle regulatory gene that inhibits G1 progression. As
shown in Supplementary Table 4,CDKN1Bhas HNF-1
binding motif according to TRANSFAC dataset [21].
The cell cycle analysis using flow cytometry also
suggests that HNF-1b act as inhibitor of cell cycle
progression. Suppression of HNF-1b significantly
increased cell population in S-phase. Taken together,
observation of clinical cases as well as ovarian cancer
cell lines indicates that OCCC generally grows slower
than serous adenocarcinoma, which may partly be
ascribed to the overexpression of HNF-1b in OCCC
[3].
It is well documented that cancer cells exhibit
unusually active metabolic processes when compared
with normal cells. This “metabolic switch” in cancer
cells is most prominent with regard to glucose
metabolism [22–24]. In this study, we incidentally
noticed that the culture media over time retained its
red coloration from the phenol red (which is indica-
tive of a more basic pH levels) in spite of the increased
growth rate of the HNF-1b-knockdown RMG2 cells,
suggesting that these cellsmaybe secreting less lactate
into the media. Indeed, measurement of lactate
indicated that both RMG2-HNF1b-sh1 and RMG2-
HNF1b-sh2 show significantly less efflux of lactate
when compared with the RMG2-control. We then
evaluated glucose uptake in these cells and found that
it is also significantly lower in RMG2-HNF1b-sh1 and
RMG2-HNF1b-sh2 cells than in the RMG2-control
cells. Expression of the glucose transporter GLUT1
mRNA aswell as GLUT1 proteinwas found to be lower
in RMG2-HNF1b-sh1 and RMG2-HNF1b-sh2 than in
the RMG2-control cells. Conversely, forced expres-
sion of HNF-1b in Hey cells increased glucose uptake
as well as expression of GLUT1. Furthermore, the
observed significant reduction in glucose uptake in
RMG2cells followingGLUT1knockdownconfirmed a
major role of GLUT1 in mediating glucose transport
in these cells (Supplementary Figure 1). In addition,
GLUT1 had HNF-1 binding motif according to
TRANSFAC dataset provided by Jeffrey T. et al.
(2006) [21] (Supplementary Table 4). These data
suggest that HNF-1b increases glucose uptake at least
in part by upregulating a glucose transporter gene.
We further evaluated the role of HNF-1b in glucose
metabolism using an assay that measures glycolytic
flux within cells. Knockdown of HNF-1b in RMG2
cells decreased the glycolytic flux rate in comparison
with the control cells, while forced expression ofHNF-
1b inHey cells had the opposite effect, suggesting that
HNF-1b not only increases glucose uptake but also
promotes glycolysis in cancer cells. In fact, further
evaluation of gene expression related to the enzymat-
ic activity associated with the glycolytic process
revealed that a majority of the genes examined were
repressed by HNF-1b knockdown. As shown in
Supplementary Table 4, some of these glycolytic
enzymes have HNF-1 binding motif according to
TRANSFAC dataset [21]. It has been reported that
activation of HIF-1a causes upregulation of GLUT1,
glucose uptake, and glycolysis under hypoxic con-
ditions [25–27]. Stany et al. [28] also showed that HIF-
a pathway was activated as one of specific signaling
pathways related to glucose metabolism in OCCC
compared with those in high-grade serous ovarian
cancer. HIF-1a protein is regulated at the posttransla-
tional level via the ubiquitin-proteasome system
under normoxic condition. In this study, we found
that HNF-1b did not alter either mRNA or protein
expressions of HIF-1a (Supplementary Figure 3).
Therefore, HNF-1b is not likely to affect transcrip-
tional or posttranscriptional levels of HIF-1a protein.
On the other hand, HIF-2a is highly homologous and
has similar binding motif as HIF-1a [29]. Therefore,
we cannot exclude the possibility that HNF-1bmight
regulate the glycolytic pathway through HIF-2a.
The characteristically high glycolytic rate in cancer
cells was first described by Otto Warburg and is
referred to as the “Warburg effect” [30]. According to
Warburg’s observations, unlike normal tissue cells,
cancer cells use glycolysis instead of using mitochon-
drial oxidative phosphorylation to obtain ATP, which
leads to high glucose consumption and lactate
production. Although not completely understood, it
is presumed that this mechanism is used to meet the
metabolic requirements to support rapid proliferation
of cancer cells. Indeed, a similar metabolic switch is
sometimes observed in normal physiological process-
es, such as embryonic development, wound healing,
or immune reactions during which rapid cell prolifer-
ation is required [22]. In cancer cells, some oncogenic
alterations have been shown to evoke the Warburg
effect [31–34]. In this study, for the first time, we
demonstrated that an important function of HNF-1b
is to promote the glycolytic process, namely the
Warburg effect.
The reason why HNF-1b functions in this manner
in OCCC is yet to be elucidated. However, it is
noteworthy that this study also found that HNF-1b
suppresses cell proliferation along with promoting
glycolysis. Hence, increased glycolytic metabolism
does not occur in parallel to increased cell prolifera-
tion with regard to HNF-1b function, similar to the
case of many oncogenes [35]. These findings may
indicate that the reasons for overexpression of HNF-
1b in OCCC may not necessarily be to meet energy
requirements for cell proliferation. Inversely, serous
ovarian cancer, typically more rapidly growing
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tumors than OCCC, seldom show HNF-1b over-
expression. Recently, elevated glycolytic rates have
been shown to contribute to the inhibition of
oxidative stress-induced apoptosis in cancer cells as
well as in normal cells, under some conditions
[36,37]. We have shown that OCCC arises in the
extraordinarily stressful environment of oxygen free
radical-enriched endometriotic cysts and expresses
significantly more stress-related genes as compared to
other histologic types of epithelial ovarian cancers [8].
In this context, HNF-1b may act as a stress-reducer
that allows for survival of OCCC cells, although
further study is needed to test this hypothesis.
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